Plus Therapeutics Inc(PSTV) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.27 | Insider Own | 0.99% | Shs Outstand | 6.9M | Perf Week | 1.04% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | 40.7% | Insider Trans | - | Shs Float | 6.8M | Perf Month | -6.97% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.88 | Inst Own | 13.85% | Short Float | 10.42% | Perf Quarter | -36.97% |
| Income | -0.02B | P/S | 5.14 | EPS this Y | 45.1% | Inst Trans | -2.1% | Short Ratio | 4.39 | Perf Half Y | -36.84% |
| Sales | 0.01B | P/B | 1.8 | EPS next 5Y | 64.84% | ROA | -99.41% | Short Interest | 0.71M | Perf YTD | -69.78% |
| Book/sh | 2.15 | P/C | 1.76 | EPS past 3/5Y | 70.82% 59.95% | ROE | - | 52W High | -83.48% ($23.42) | Perf Year | -67.95% |
| Cash/sh | 2.2 | P/FCF | - | Sales past 3/5Y | 185.5% 76.66% | ROIC | -132.86% | 52W Low | 33.45% ($2.90) | Perf 3Y | -93.71% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 96.28% | Gross Margin | 92.8% | Volatility(W/M) | 5.24% 6.59% | Perf 5Y | -99.46% |
| Dividend TTM | - | EV/Sales | 2.36 | Sales Y/Y TTM | -0.46% | Oper. Margin | -364.36% | ATR (14) | 0.28 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 2.21 | EPS Q/Q | 96.5% | Profit Margin | -306.66% | RSI (14) | 44.03 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.21 | Sales Q/Q | -2.93% | SMA20 | -0.49% ($3.89) | Beta | 1.43 | Target Price | $39.67 |
| Payout | - | Debt/Eq | 0.06 | Earnings | 2026/5/15 | SMA50 | -16.95% ($4.66) | Rel Volume | 0.59 | Prev Close | $3.65 |
| Employees | 28 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -23.82% 5.54% | SMA200 | -54.07% ($8.43) | Avg Volume(3M) | 0.16M | Price | $3.87 |
| IPO | 2003/10/22 | Option/Short | No/Yes | Trades | 527 | Volume | 95,649 | Change | 6.03% |
🧬 The company is a CNS (central nervous system) oncology specialist developing radiopharmaceuticals and diagnostics. It uses rhenium-186 nanoliposome-based radiotherapeutic REYOBIQ to treat rare brain tumors such as glioblastoma and meningeal metastases, and is commercializing CNSide, a cerebrospinal fluid diagnostic test. The company has secured insurance coverage covering 67 million lives, including Humana.
Over the past 1 year, on the lower side
83% below its 1-year high.
Traded less than usual. That is 59% of its average volume.
PSTV has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +45.1% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $514. Peers typically go for $1,010.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.5%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 13.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #455 of 598 in the industry
Based on market cap of $27M.
ABVC#454 ABVC BioPharma Inc $27M PER - PSTV#455 Plus Therapeutics Inc $27M PER - 
BYSI#455 BeyondSpring Inc $26M PER - 
BCTX#456 BriaCell Therapeutics Corp $26M PER - 
CELU#457 Celularity Inc $26M PER - 
FAQ
What kind of company is PSTV?
PSTV belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PSTV?
The market cap of PSTV is approximately $27M, ranking 5,172 within its sector.
What is the 52-week high and low for PSTV?
PSTV has recorded a 52-week high of $23.42 and a low of $2.90.
